(Total Views: 414)
Posted On: 12/12/2019 9:40:59 AM
Post# of 157045
misiu is correct in that, so far, there has been no documented HIV resistance to leronlimab.
I share your question/concern about cancer. The answer is that, right now, I think no one knows if cancer will eventually find a "workaround" to metastasize without CCR5 involvement. As the famous line from "Jurassic Park" goes, "life finds a way".
With that said, even if cancer did eventually find a workaround to metastasize without CCR5 involvement, any drug that increases overall survival (OS) meaningfully will be approved.
In mTNBC, for example, I think median OS is somewhere between 10-14 months.
A drug that pushed that to 20 months, for example, would be groundbreaking.
So, for cancer, while it would obviously be great if leronlimab stopped metastasis forever, it doesn't need to do that to help patients, get approved, and make us money.
I share your question/concern about cancer. The answer is that, right now, I think no one knows if cancer will eventually find a "workaround" to metastasize without CCR5 involvement. As the famous line from "Jurassic Park" goes, "life finds a way".
With that said, even if cancer did eventually find a workaround to metastasize without CCR5 involvement, any drug that increases overall survival (OS) meaningfully will be approved.
In mTNBC, for example, I think median OS is somewhere between 10-14 months.
A drug that pushed that to 20 months, for example, would be groundbreaking.
So, for cancer, while it would obviously be great if leronlimab stopped metastasis forever, it doesn't need to do that to help patients, get approved, and make us money.
(1)
(0)
